Reviva Pharmaceuticals Awaits FDA Feedback on Brilaroxazine Formulation Change Ahead of Phase 3 RECOVER-2 Enrollment

Reviva Pharmaceuticals is navigating a mid-development formulation change for brilaroxazine that will require FDA alignment before RECOVER-2 enrollment can begin, a sequence that regulatory affairs teams managing late-stage CNS programs will recognize as a high-stakes dependency chain. The company expects FDA feedback in Q4 2026 on whether the new drug form can be incorporated into both the registrational Phase 3 trial and the planned NDA submission for schizophrenia.

The new form of brilaroxazine is the subject of a U.S. composition of matter patent application filed under an accelerated review request. If granted, the filing would extend patent life and commercial exclusivity through 2046. The strategic logic is straightforward: locking in the new form now, before Phase 3 enrollment, avoids a more disruptive reformulation later in the development cycle and aligns the commercial asset with the clinical dossier from the outset.

Pending FDA feedback, Reviva intends to initiate a bridging bioequivalence study in Q4 2026 to confirm comparability between the new and existing formulations. That study is a prerequisite for incorporating the new form into RECOVER-2 and the NDA, a regulatory pathway that mirrors ICH Q12 principles on post-approval and late-development chemistry, manufacturing, and controls changes. Patient enrollment in RECOVER-2 is targeted for 1H 2027, contingent on both FDA clearance and receipt of additional financing.

For QA and regulatory leads, the bioequivalence bridge is the critical control point. Any gap between FDA's formulation acceptance and the bioequivalence data package could compress the timeline between enrollment initiation and NDA readiness. The company's Q2 2026 cash position of approximately $19.9 million, up from $14.4 million at year-end 2025, provides some runway, though the financing condition attached to enrollment adds execution risk that supply-chain and clinical operations teams should factor into site-readiness planning.

Separately, clinical data from the earlier RECOVER Phase 3 trial, including vocal biomarker findings from patients with negative symptoms, have been published in Biological Psychiatry, adding peer-reviewed weight to the brilaroxazine schizophrenia program ahead of the NDA build.

The Q4 2026 FDA feedback window will determine whether Reviva's formulation strategy holds or requires renegotiation before RECOVER-2 sites can open.

Source: Reviva Pharmaceuticals via GlobeNewswire, August 12, 2026.